Cipla Ltd stated that it will focus on regulatory compliance across manufacturing locations and it will scale up businesses across branded and generic direct-to-market (DTMs) of Europe and emerging markets through execution on organic and partnered launches including biosimilars.

The company's near-term priorities include a continued execution on the demand levers in the chronic and acute therapies, improving the manpower productivity across branded and generic markets of India and South Africa.

Kedar Upadhye, global CFO, Cipla Ltd in a conference call said, "We continue to see strong traction in our US revenue run rate both on a sequential and YoY basis led by further expansion in the Albuterol share and continued respiratory unlocking with the addition of Arformoterol in our portfolio. This has helped us offset the erosion seen in the rest of the portfolio. Our profitability for the quarter continues to track well above our full year targets. We believe that there is reasonable headroom to drive EBITDA on a full year basis versus fiscal 2021.The portfolio momentum continues to be on track with solid double-digit growth during the quarter."

For the first quarter ended June 30, 2021, the company posted 24% rise in net profit at Rs. 715 crore for the first quarter ended June 30, 2021.The company's income from operations stood at Rs. 5,504 crore.

The company stated that the growth in operating profitability and prudent working capital management drives robust free cash flow generation.

“In India, we maintained our market beating performance as core therapies responded to demand triggers along with support from covid portfolio during the second wave. Our South Africa private business continues to outperform the market," stated Umang Vohra MD and Global CEO, Cipla Ltd